Glibenclamide: An old drug with a novel mechanism of action?

Acta Diabetologica

Volumn 34, Issue 4, 1997, Pages 239-244

  Luzi, L ^a   Pozza, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); C PEPTIDE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; GLUCOSE; INSULIN; METFORMIN; POTASSIUM CHANNEL; SULFONYLUREA; TOLAZAMIDE; TOLBUTAMIDE;

DEPOLARIZATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG MECHANISM; HEART MUSCLE; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INTESTINE ABSORPTION; LIVER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL DRUG ADMINISTRATION; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE; SMOOTH MUSCLE;

ADIPOSE TISSUE; C-PEPTIDE; CENTRAL NERVOUS SYSTEM; DIABETES MELLITUS, TYPE 2; GLYBURIDE; HEART; HUMANS; HYPOGLYCEMIC AGENTS; ISLETS OF LANGERHANS; LIVER; MUSCLE, SKELETAL; POTASSIUM CHANNELS;

EID: 0031463342     PISSN: 09405429     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005920050081     Document Type: Review

References (59)

1. Koltermann OG, Gray RS, Shapiro G, Scarlett JA, Griffin J, Olefsky JM, The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects. Diabetes 33:346-354, 1984
2. Lebovitz HE, Feinglos MN, Bucholtz HK, Lebivitz FL, Potentiation of insulin action: a probable mechanism for the antidiabetic action of sulfonylurea drugs. J Clin Endocrinol Metab 45:601-604, 1977
3. Simonson DC, Ferrannini E, Bevilacqua S, Smith D, Barrett E, Carlson R, De Fronzo RA, Mechanism of improvement in glucose metabolism after chronic glyburide therapy. Diabetes 33:838-845, 1984
4. Pfeifer MA, Halter JB, Graf R, Porte D Jr, Potentiation of insulin secretion to non-glucose stimuli in normal man by tolbutamide. Diabetes 29:335-340, 1980
5. Groop L, Luzi L, Melander A, Groop P-H, Ratheiser K, Simonson DC, DeFronzo RA, Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects. Diabetes 36:1320-1328, 1987
6. Krall LP, Oral hypoglycemic agents. In: Joslin's diabetes mellitus, 12th edn. Lea & Febiger, Philadelphia, pp 412-452, 1985
7. Boyd AE III, Sulphonylurea receptors, ion channels and fruit flies. Diabetes 37:847-850, 1988
8. Eliasson L, Renstrom E, Ammala C, Berggren P-O, Bertorello AM, Bokvist K, Chibalin A, Deeney JT, Flatt PR, Gabel J, Gromada J, Larsson O, Lindstrom P, Rhodes CJ, Rorsman P, PKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic β-cells. Science 271:813-815, 1996
9. Revers R, Fink R, Griffin J, Olefsky J, Koltermann O, Influence of hyperglycemia on insulin's in vivo effects in type II diabetes. J Clin Invest 73:664-672, 1984
10. Johansson BL, Borg K, Fernqvist-Forbes E, Odergren T, Remahl S, Wahren J, C-peptide improves autonomic nerve function in IDDM patients. Diabetologia 39:687-95, 1996
11. Vindigni IA, Chang K, Stramm L, Chance R, Heath WF, DiMarchi RD, Di Cera E, Williamson JR, Prevention of vascular and neural dysfunction in diabetic rats by c-peptide. Science 277:563-566, 1997
12. Lebovitz HE, Feinglos MN, The oral hypoglycemic agents. In: Ellenberg M, Rifkin H (eds) Diabetes mellitus, theory and practice, 3rd edn. Medical Examination Publishing, New Hyde Park, New York, pp 591-610, 1983
13. Ferner RE, Neil HAW, sulfonylureas and hypoglycemia. BMJ 246:949-950, 1988
14. Groop LC, Luzi L, De Fronzo RA, Melander A, Hyperglycemia and absorption of sulfonylurea drugs. Lancet 2:129-130, 1989
15. Whalin-Boll E, Almer LO, Melander A, Bioavailability, kinetics and effects of glipizide in type 2-diabetics. Clin Pharmacokinet 7:363-372, 1982
16. Groop LC, Barzilai N, Ratheiser K, Luzi L, Melander A, De Fronzo R, Dose-dependent effect of glibenclamide on insulin secretion and glucose uptake in man. Diabetes Care 14:724-727, 1991
17. Luzi L, De Fronzo RA, Effect of the loss of first phase of insulin secretion on hepatic glucose production and tissue glucose disposal in humans. Am J Physiol 257:E241-E246, 1989
18. De Fronzo RA, Binder C, Wahren J, Felig P, Ferrannini E, Faber OK, Sensitivity of insulin secretion to feedback inhibition by hyperinsulinaemia. Acta Endocrinol 98:81-86, 1981
19. Luzi L, Battezzati A, Perseghin G, Bianchi E, Vergani S, Secchl A, La Rocca E, Staudacher C, Spotti D, Ferrari G, Di Carlo V, Pozza G, Lack of feed-back inhibition of insulin secretion in denervated human pancreas. Diabetes 41:1632-1639, 1992
20. Leclercq-Meyer V, Malaisse WJ, Johansson BL, Wahren J, Effect of C-peptide on insulin and glucagon release by isolated perfused rat pancreas. Diabetes Metab 23:149-154, 1997
21. Inoue Y, Emoto M, Inoue H, Kaku K, Kaneko T, Characterization of the binding sites for 3H-glibenclamide in rat liver membranes. Eur J Pharmacol 284:77-82, 1995
22. Atalay T, Altan N, Ongun CO, Alagol H, Effect of sulfonylurea glyburide on glycogen synthesis in alloxan-induced diabetic rat hepatocytes. Pharmacology 25:1435-1437, 1994
23. Tiedge M, Lenzen S, Effects of glucose refeeding and glibenclamide treatment on glucokinase and GLUT2 gene expression in pancreatic B-cells and liver from rats. Biochem J 308:139-144, 1995
24. Kern M, Loomis TA, Tpscott EB, Dohm GL, Increase muscle glucose uptake in response to chronic glyburide treatment is not related to changes in glucose transporter (GLUT 4) protein. Int J Biochem 25:1257-1261, 1993
25. Lopez-Alarcon L, Munoz-Alonso MJ, Guijarro C, Feliu JE, Modulation of glycogen phosphorylase activity and fructose 2,6-bisphosphate levels by glibenclamide and meglitinide in isolated rat hepatocytes: a comparative study. Metabolism 44: 1000-1007, 1995
26. Chen H, Hamel FG, Silford G, Duckworth WC, Alteration of rat hepatic insulin metabolism by glyburide and glipizide. J Pharmacol Exp Ther 264:1293-1298, 1993
27. Barzilai N, Groop P-H, Groop L, DeFronzo RA, A novel mechanism of glipizide sulfonylurea action: decreased metabolic clearance rate of insulin. Acta Diabetol 32:273-278, 1995
28. Kahn CR, Shechter Y, Insulin, oral hypoglycemic agents and the pharmacology of the endocrine pancreas. In: Goodman and Gilman's The pharmacological basis of therapeutics, 8th edn. Pergamon Press, pp 1463-1495, 1985
29. Tsiani E, Ramlal T, Leiter LA, Klip A, Fantus IG, Stimulation of glucose uptake and increase of plasma membrane content of glucose transporters in L6 skeletal muscle cells by the sulfonylureas gliclazide and glyburide. Endocrinology 136:2505-2512, 1995
30. Rajan AS, Luo ZT, Kahan BB, Comstock JP, Cushmann SW, Boyd AE 3rd, Do adipocytes contain high affinity sulfonylurea receptors. Endocrinology 134:1581-1588, 1994
31. Wu W, Oshida Y, Yang WP, Li L, Ohsawa I, Sato J, Iwao S, Johansson BL, Wahren J, Sato Y, Effect of C-peptide administration on whole body glucose utilization in STZ-induced diabetic rats. Acta Physiol Scand 157:253-258, 1996
32. University Group Diabetes Program, A story of the effects of hypoglycemic agents on vascular complications in patients with adult onset diabetes. II. Mortality results. Diabetes 19:789-830, 1970
33. American Diabetes Association, Policy statement: the UGDP controversy. Diabetes 28:168-170, 1979
34. Lomuscio A, Vergani D, Marano L, Castagnone M, Fiorentini C, Effect of glibenclamide on ventricular fibrillation in non-insulin dependent diabetics with acute myocardial infarction. Coron Artery Dis 5:767-771, 1994
35. Tosaki A, Engelman DT, Engelman RM, Das DK, Diabetes and ATP-sensitive potassium channel openers and blockers in isolated ischemic/reperfused hearts. J Pharmacol Exp Ther 275: 115-1123, 1995
36. Hoffman D, Opie LH, Potassium channel blockade and acute myocardial infarction: implications for management of the non-insulin requiring diabetic patient. Eur Heart J 14:1585-1589, 1993
37. Pogatsa G, Potassium channel in the cardiovascular system. Diabetes Res Clin Prac 28:891-98, 1995
38. Zini S, Tremblay E, Roisin M, Ben-Ari Y, Regional distribution of sulfonylurea receptors in the brain of rodent and primate. Brain Res 542:151-154, 1991
39. Bernardi H, Fosset M, Lazdunski M, ATP/ADP binding sites are present in the sulfonyluea binding protein associated with brain ATP-sensitive K channels. Biochemistry 31:6328-6332, 1992
40. During MJ, Leone P, Davis KE, Kerr D, Sherwin RS, Glucose modulates rat substantia nigra GABA release in vivo via ATP-sensitive potassium channels. J Clin Invest 95:2403-2408, 1995
41. Dunn-Meynell AA, Routh VH, McArdle JJ, Levin BE, Low-affinity sulfonylurea binding sites reside on neuronal cell bodies in the brain. Brain Res 745:1-9, 1997
42. Heurteaux C, Bertaina V, Widmann C, Lazdunski M, K+ channel openers prevent global ischemia-induced expression of c-fos, c-jun, heat shock protein, and amyloid β-protein precursor genes and neuronal death in rat hippocampus. Proc Natl Acad Sci 90:9431-9435, 1993
43. Wu CW, Leung CK, Yung WH, Sulfonylureas reverse hypoxia induced K(+)-conductance increase in substantia nigra pars reticulata neurones. Neuroreport 7:2513-2517, 1996
44. Kitano I, Mori N, Matsunaga T, Role of ATP-sensitive K+ channels in anoxia-sensitive negative potential of endolymph. Hear Res 90:24-30, 1995
45. Armstead WM, Role of nitric oxide, cyclic nucleotides, and the activation of ATP-sensitive K+ channels in the contribution of adenosine to hypoxia induced pial artery dilation. J Cereb Blood Flow Metab 17:100-108, 1997
46. Armsted WM, Role of ATP-sensitive K+ channels in cGMP-mediated pial artery vasodilation. Am J Physiol:H423-H426, 1996
47. Nishimura M, Takahashi H, Nanbu A, Sakamoto M, Nakanishi T, Yoshimura M, Cerebral adenosine triphosphate-sensitive K+ channels may be impaired during acute cerebral ischemia in spontaneously hypertensive rats. J Auton Nerve Syst 58:139-146, 1996
48. Nishimura M, Takahashi H, Nanbu A, Sakamoto M, Nakanishi T, Yoshimura M, Cerebral ATP-sensitive potassium channels during acute reduction of carotid blood flow. Hypertension 25: 1069-1074, 1995
49. Amoroso S, Schmid-Antomarchi H, Fosset M, Lazdunski M, Glucose sulfonylureas and neurotransmitter release: role of ATP-sensitive K channels. Science 247:852-854, 1990
50. Mourre C, Widmann C, Lazdunski M, Specific hippocampal lesions indicate the presence of sulfonylurea binding sites associated to ATP-sensitive K channels both post-synaptically and on mossy fibers. Brain Res 540:340-344, 1991
51. Gandolfo G, Gottesman C, Bidard J-N, Lazdunski M, K+ channel openers prevent epilepsy induced by the bee venom peptide MCD. Eur J Pharmacol 167:181-183, 1989
52. Johansson BL, Kernell A, Sjoberg S, Wahren J, Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes type 1. J Clin Endocrinol Metab 77:976-81, 1993
53. Luzi L, Secchi A, Pozza G, Metabolic assessment of post-transplantation islet function in humans. Methodological considerations and possible pitfalls: a lesson from pancreas transplantation. In: Ricordi R (ed) Landes, Pancreatic islet cell transplantation, pp 361-382, 1992
54. Luzi L, Battezzati A, Perseghin G, Bianchi E, Terruzzi I, Spotti D, Vergani S, Secchi A, La Rocca E, Ferrari G, Staudacher C, Castoldi R, Di Carlo V, Pozza G, Combined pancreas and kidney transplantation normalizes protein metabolism in insulin-dependent diabetic-uremic patients. J Clin Invest 93:1948-1958, 1994
55. Luzi L, Hering BJ, Socci C, Raptis G, Battezzati A, Terruzzi I, Falqui L, Braundhorts H, Braundhorst D, Regalia E, Brambilla E, Secchl A, Perseghin G, Maffi P, Bianchi E, Mazzaferro V, Gennari L, Di Carlo V, Federlin K, Pozza G, Bretzel R, Metabolic effects of successfull intraportal islet transplantation on glucose metabolism in IDDM. J Clin Invest 97:2611-2618, 1996
56. Anonymous, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977-986, 1993
57. Solders G, Tyden G, Persson A, Groth GC, Improvement in diabetic neuropathy 4 years after successful pancreatic and renal transplantation. Diabetologia 34 (S1):S125-S127, 1991
58. Martinenghi S, Comi G, Galardi G, Di Carlo V, Pozza G, Secchi A, Amelioration of nerve conduction velocity following simultaneous kidney/pancreas transplantation is due to the glycaemic control provided by the pancreas. Diabetologia 40:1110-1112, 1997
59. Ramsay RC, Goetz FC, Sutherland DE, Mauer SM, Robison LL, Cantrill HL, Knobloch WH, Najarian JS, Progression of diabetic retinopathy after pancreas transplantation for insulin-dependent diabetes mellitus. N Engl J Med 318:208-214, 1988